SLC25A12 and prostate adenocarcinoma: SLC25A8 and SLC25A12 also had high expression levels in some cancer such as colon adenocarcinoma, bladder urothelial carcinoma, prostate adenocarcinoma, breast invasive cancer, and uterine corpus endometrial carcinoma.